Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$3.61 -3.5%	$2.55	$1.89 ▼ $4.09	$1.12B	0.36	3.34 million shs	6.19 million shs
AUPH Aurinia Pharmaceuticals	$8.64 +0.1%	$8.07	$5.20 ▼ $10.67	$1.17B	1.15	1.36 million shs	4.36 million shs
ELVN Enliven Therapeutics	$20.68 -3.9%	$19.24	$13.30 ▼ $30.03	$1.06B	0.79	299,814 shs	1.44 million shs
FHTX Foghorn Therapeutics	$4.84 -0.4%	$4.37	$2.94 ▼ $10.25	$270.90M	3.04	145,841 shs	870,126 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-1.58%	+7.78%	+88.89%	+61.90%	+34.05%
AUPH Aurinia Pharmaceuticals	+7.47%	+8.96%	+5.89%	+4.10%	+56.62%
ELVN Enliven Therapeutics	+0.09%	-0.23%	+34.58%	+2.14%	+1.61%
FHTX Foghorn Therapeutics	-0.82%	+2.32%	+20.00%	+38.07%	-11.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.3451 of 5 stars	3.4	1.0	3.1	3.3	0.0
AUPH Aurinia Pharmaceuticals	2.7235 of 5 stars	3.5	1.0	2.8	0.8	1.9
ELVN Enliven Therapeutics	2.2389 of 5 stars	3.5	0.0	2.5	4.2	0.0
FHTX Foghorn Therapeutics	1.977 of 5 stars	3.6	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.75	Moderate Buy	$8.33	130.84% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.10% Upside
ELVN Enliven Therapeutics	3.00	Buy	$39.60	91.49% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	150.52% Upside

Current Analyst Ratings Breakdown

Latest FHTX, AUPH, ELVN, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/16/2025	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $10.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	37.37	N/A	N/A	$3.58 per share	1.01
AUPH Aurinia Pharmaceuticals	$235.13M	4.96	$0.31 per share	27.98	$2.68 per share	3.22
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	11.94	N/A	N/A	($0.82) per share	-5.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/5/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.86	15.43	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)

Latest FHTX, AUPH, ELVN, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
ELVN Enliven Therapeutics	N/A	21.07	21.06
FHTX Foghorn Therapeutics	N/A	3.16	3.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
AUPH Aurinia Pharmaceuticals	36.83%
ELVN Enliven Therapeutics	95.08%
FHTX Foghorn Therapeutics	61.55%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
AUPH Aurinia Pharmaceuticals	12.20%
ELVN Enliven Therapeutics	25.90%
FHTX Foghorn Therapeutics	7.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable

FHTX, AUPH, ELVN, and ABCL Headlines

Recent News About These Companies

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Buy" by Brokerages

June 4, 2025 | marketbeat.com

Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025

May 22, 2025 | quiverquant.comQ

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

May 22, 2025 | globenewswire.com

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2025 | zacks.com

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

May 14, 2025 | globenewswire.com

Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Up 5.95%

May 13, 2025 | aaii.comA

Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 5.19%

May 9, 2025 | aaii.comA

Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles

May 7, 2025 | investing.com

Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 8.12%

May 7, 2025 | aaii.comA

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

May 5, 2025 | globenewswire.com

Foghorn Therapeutics expands board with biotech veterans

May 2, 2025 | investing.com

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

May 1, 2025 | globenewswire.com

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

April 28, 2025 | globenewswire.com

JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation

April 23, 2025 | msn.com

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

April 15, 2025 | globenewswire.com

Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients

March 26, 2025 | seekingalpha.com

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

March 25, 2025 | globenewswire.com

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

March 6, 2025 | zacks.com

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

March 6, 2025 | globenewswire.com

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses

February 28, 2025 | finance.yahoo.com

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

February 27, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, AUPH, ELVN, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$3.61 -0.13 (-3.48%)

Closing price 04:00 PM Eastern

Extended Trading

$3.60 -0.01 (-0.42%)

As of 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.64 +0.01 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$8.62 -0.02 (-0.23%)

As of 07:57 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Enliven Therapeutics NASDAQ:ELVN

$20.68 -0.84 (-3.90%)

Closing price 04:00 PM Eastern

Extended Trading

$20.68 0.00 (0.00%)

As of 05:18 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Foghorn Therapeutics NASDAQ:FHTX

$4.84 -0.02 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$4.84 0.00 (0.00%)

As of 04:34 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time